<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05023304</url>
  </required_header>
  <id_info>
    <org_study_id>The Prepare Study</org_study_id>
    <nct_id>NCT05023304</nct_id>
  </id_info>
  <brief_title>In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery</brief_title>
  <acronym>Prepare</acronym>
  <official_title>In Clinic Optometrist Insertion of Dextenza Prior to Cataract Surgery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Mitchel Ibach</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ocular Therapeutix, Inc.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Vance Thompson Vision</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To evaluate the clinical outcomes with optometrist pre-surgical insertion of DEXTENZA in the&#xD;
      clinical office setting in patients undergoing same-day cataract surgery compared to standard&#xD;
      of care steroid therapy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 23, 2021</start_date>
  <completion_date type="Anticipated">October 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 27, 2022</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Care Provider, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean anterior chamber cell/flare score</measure>
    <time_frame>post-op Day 1</time_frame>
    <description>Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 + (SUN Working Group Grading Scheme)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean anterior chamber cell/flare score</measure>
    <time_frame>post-op Day 7</time_frame>
    <description>Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 + (SUN Working Group Grading Scheme)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean anterior chamber cell/flare score</measure>
    <time_frame>post-op Week 4.</time_frame>
    <description>Mean anterior chamber cell/flare score measured by Slit Lamp Biomicroscopy evaluation using grading scale of 0 to 4 + (SUN Working Group Grading Scheme)</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean pain score</measure>
    <time_frame>post-op Day 1</time_frame>
    <description>Mean pain score measured by Visual Analog Score numerical grading scale 0-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean pain score</measure>
    <time_frame>post-op Day 7</time_frame>
    <description>Mean pain score measured by Visual Analog Score numerical grading scale 0-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean pain score</measure>
    <time_frame>post-op Week 4</time_frame>
    <description>Mean pain score measured by Visual Analog Score numerical grading scale 0-10</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient preference</measure>
    <time_frame>post-op Week 4</time_frame>
    <description>As measured by adapted COMTOL (Comparison of Ophthalmic Medications for Tolerability) Questionnaire</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of increased intraocular pressure (IOP) &gt;10mmHg above baseline</measure>
    <time_frame>postop Day 1</time_frame>
    <description>Incidence of increased intraocular pressure (IOP) &gt;10mmHg above baseline as measured by Goldmann Applanation Tonometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of increased intraocular pressure (IOP) &gt;10mmHg above baseline</measure>
    <time_frame>postop Day 7</time_frame>
    <description>Incidence of increased intraocular pressure (IOP) &gt;10mmHg above baseline as measured by Goldmann Applanation Tonometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of increased intraocular pressure (IOP) &gt;10mmHg above baseline</measure>
    <time_frame>postop Week 4</time_frame>
    <description>Incidence of increased intraocular pressure (IOP) &gt;10mmHg above baseline as measured by Goldmann Applanation Tonometer</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of Cystoid Macular Edema (CME)</measure>
    <time_frame>post-op Week 4</time_frame>
    <description>Incidence of Cystoid Macular Edema (CME) as measured by optical coherence tomography (OCT)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Physician Ease of Use</measure>
    <time_frame>Day 0</time_frame>
    <description>Physician Ease of Use Survey following dexamethasone intracanalicular placement on Surgical Visit</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye Drop Burden</measure>
    <time_frame>post-op Day 7</time_frame>
    <description>Eye Drop Burden Questionnaire numerical grading scale of 1-5</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Eye Drop Burden</measure>
    <time_frame>post-op Week 4</time_frame>
    <description>Eye Drop Burden Questionnaire numerical grading scale of 1-5</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Cataract</condition>
  <arm_group>
    <arm_group_label>Group A Dextenza</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Group B Topical Prednisolone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Dextenza 0.4Mg Ophthalmic Insert</intervention_name>
    <description>The insert, containing 0.4 mg of active pharmaceutical product, is placed within the canaliculus to provide a sustained and tapered delivery of drug to the ocular surface over 30 days after a one-time insertion. The attributes of the insert reduce the risks for improper corticosteroid tapering and unwanted peaks and troughs in drug concentration.</description>
    <arm_group_label>Group A Dextenza</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Topical Prednisolone</intervention_name>
    <description>Standard of care topical drop treatment</description>
    <arm_group_label>Group B Topical Prednisolone</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Patients 18 years of age or older, undergoing routine, uncomplicated, sequential&#xD;
             bilateral cataract surgery.&#xD;
&#xD;
          -  Willing and able to comply with clinic visits and study related procedures&#xD;
&#xD;
          -  Willing and able to sign the informed consent form&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients under the age of 18.&#xD;
&#xD;
          -  Patients who are pregnant (must be ruled out in women of childbearing age with&#xD;
             pregnancy test).&#xD;
&#xD;
          -  Active infectious ocular or systemic disease.&#xD;
&#xD;
          -  Patients with active infectious ocular or extraocular disease.&#xD;
&#xD;
          -  Patients actively treated with local or systemic immunosuppression including systemic&#xD;
             corticosteroids.&#xD;
&#xD;
          -  Patients with known hypersensitivity to Dexamethasone.&#xD;
&#xD;
          -  Patients with severe disease that warrants critical attention, deemed unsafe for the&#xD;
             study by the investigator.&#xD;
&#xD;
          -  Patients with proliferative diabetic retinopathy or uncontrolled diabetes as deemed by&#xD;
             an A1C &gt; 10.0.&#xD;
&#xD;
          -  Patients with a history of ocular inflammation or macular edema.&#xD;
&#xD;
          -  Patients with a pre-existing epiretinal membrane (ERM)&#xD;
&#xD;
          -  Patients with allergy or inability to receive intracameral antibiotic.&#xD;
&#xD;
          -  Patients on systemic non-steroidal anti-inflammatory drugs (NSAID) greater than 1,200&#xD;
             mg/day The PREPARE Study (V1) February, 2021 Page 27 CONFIDENTIAL&#xD;
&#xD;
          -  Patients with a corticosteroid implant (i.e. Ozurdex).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keeley Puls-Boever</last_name>
    <phone>605-361-3937</phone>
    <email>keeley.puls@vancethompsonvision.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Kristin Dunne</last_name>
    <phone>6053613937</phone>
    <email>kristin.dunne@vancethompsonvision.com</email>
  </overall_contact_backup>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 2, 2021</study_first_submitted>
  <study_first_submitted_qc>August 25, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 26, 2021</study_first_posted>
  <last_update_submitted>August 25, 2021</last_update_submitted>
  <last_update_submitted_qc>August 25, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">August 26, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Vance Thompson Vision</investigator_affiliation>
    <investigator_full_name>Mitchel Ibach</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cataract</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Prednisolone</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

